Abstract 6573: Assessment of the T cell receptor repertoire in racially diverse prostate cancer patients

作者：Paula O. Cooper, Laila Scroggins, Sally Elsamanoudi, Amina Ali, Picabo Binette, Beatriz German Falcon, Leigh Ellis, Gregory T. Chesnut, Shyh‐Han Tan, Cara C. Schafer · 发表于：Cancer Research · 年份：2026 · DOI：10.1158/1538-7445.am2026-6573 · 研究领域：Cancer Immunotherapy and Biomarkers、Prostate Cancer Treatment and Research、Single-cell and spatial transcriptomics

Abstract Background: Prostate cancer (PCa), the second leading cause of cancer-related death for US men, gains limited benefits from immune therapies. Interestingly, African American (AA) men respond far better to Sipuleucel-T and undergo different T cell responses than Caucasian American (CA) PCa patients. Growing evidence suggests that variations in TCR diversity may serve as a biomarker for cancer progression and response to immune therapy; however, the extent of the TCR repertoire’s contribution to PCa progression and disparate racial responses to treatment remains unclear, highlighting the need for further study. Purpose: The rapid development of Next Generation Sequencing and single-cell transcriptomics provides a unique opportunity to examine the TCR repertoires of PCa patients in greater depth than previously possible. By examining TCR sequences in a racially diverse cohort from an equal-access Military Health System, we aim to identify how differences in AA and CA repertoires may contribute to variations in PCa initiation, progression, and response to therapy. Methods: Bulk TCR-seq was performed on 25 AA and 30 CA treatment-naïve tumor biopsies to compare the percent of dominant and unique TCRs (D50) from each sample. Next, peripheral blood lymphocytes (PBLs) were isolated from 4 AA and 4 CA men undergoing radical prostatectomy for diagnosed PCa with no prior treatment, matched for age, Gleason score, and PSA. 10X Genomics V(D)J and GEX technologies were used to prod...